Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/enyqCrsecsaKjtttWwrl

March 19, 2013Faster News for FasterCures

  Top News 
  • Sequestration threatens faster FDA reviews, Hamburg says
    Across-the-board sequestration cuts could hurt the FDA's efforts to accelerate new drug reviews, said FDA Commissioner Dr. Margaret Hamburg during MassBio's annual meeting. Hamburg said she hopes Congress will allow the agency to put user fees paid by drugmakers toward its operating expenses. Boston Herald (3/15) LinkedInFacebookTwitterEmail this Story
  News from FasterCures 
  • Financial innovation series highlights ANTABIO and WiSeed
    In this month's series on novel R&D funding models, FasterCures profiles ANTABIO, a France-based biopharmaceutical company that partnered with the crowdfunding platform WiSeed to complete the first successful crowdfunding round for a biotechnology startup company. ANTABIO successfully raised €300,000 ($387,640) in three months from more than 200 investors through WiSeed. An accredited investor then made an approximately €500,000 ($646,218) investment and bought back the crowdfunded shares for a return on investment of 44%. Read this month's case study. LinkedInFacebookTwitterEmail this Story
  • Blog: Working together toward cures for rare diseases
    On Feb. 28, FasterCures joined friends and colleagues in the rare disease community to commemorate Rare Disease Day, the culmination of a week's worth of activities to bring widespread recognition of rare diseases as a global health challenge. We were privileged to be a part of a major event here in D.C. kick-starting the week and celebrating the screening of Here.Us.Now, a documentary highlighting the Hempel Family and their struggle to save their twin daughters, Addi and Cassi, who are living with Neimann Pick Type C. Following the screening, Margaret Anderson moderated a panel about collaborating for cures. Read more. LinkedInFacebookTwitterEmail this Story
Learn more about FasterCures ->FasterCures Home  |  Milken Institute

 

  Science and Technology 
  • Researchers, advocates say Alzheimer's funding is inadequate
    Alzheimer's disease has become the sixth-leading cause of death in the U.S., while death rates related to stroke, HIV and breast cancer have declined. The Alzheimer's Association, along with doctors and researchers, are calling for increased funding to find effective treatments and cures. Funding for NIH research into Alzheimer's was expected to increase this year, but levels are uncertain in light of sequestration and many meritorious grant applications have gone unfunded, says Mayo Clinic neurology professor David Knopman. Bloomberg (3/19), Yahoo/The Associated Press (3/19) LinkedInFacebookTwitterEmail this Story
  • Early treatment may functionally cure some HIV patients
    Fourteen HIV patients who received very early treatment showed no signs of the virus rebounding seven years after ceasing treatment, researchers report in PLoS Pathogens. "Early treatment in these patients may have limited the establishment of viral reservoirs, the extent of viral mutations, and preserved immune responses," said researcher Christine Rouzioux. Reuters (3/15) LinkedInFacebookTwitterEmail this Story
  Finance and Economics 
  • Drugmakers cut antibiotics R&D as superbugs take hold
    Despite concerns about drug-resistant bacteria, few drugmakers are developing new antibiotics and some have trimmed their antibiotics research spending. Regulatory hurdles and relatively low market pricing make antibiotics development unattractive. Public-private partnerships might shift the playing field, and more research sharing could boost innovation, GlaxoSmithKline CEO Andrew Witty said. Reuters (3/18) LinkedInFacebookTwitterEmail this Story
  • GSK CEO: Efficiencies will drive down drug prices
    Advances in research and development efficiencies should lead to lower prices for new drugs, GlaxoSmithKline CEO Andrew Witty said. Drugmakers are seeing greater success, with 39 new drugs approved last year, and some companies are seeing lower average per-drug development costs. Global demand for drugs is also rising, which should drive down per-unit costs, Witty said. Reuters (3/14) LinkedInFacebookTwitterEmail this Story
  Policy and Regulation 
  • Senator seeks return for taxpayers on drugs fueled by public funds
    Sen. Ron Wyden, D-Ore., has asked NIH Director Dr. Francis Collins for documents related to the development of Pfizer's new arthritis drug Xeljanz, which was initially developed in collaboration with the NIH. The drug's monthly wholesale price is $2,055, much of which will be borne by Medicare, but Pfizer says it invested 20 years and $1 billion into the drug. "In the face of this difficult economic climate and the increasing scarcity of research dollars it is time to revisit the idea of striking a better balance between encouraging profit, innovation, accessibility and affordability," Wyden wrote in an open letter. The New York Times (tiered subscription model) (3/18) LinkedInFacebookTwitterEmail this Story
  • Proposed budget hike would increase FDA oversight in China
    A Senate bill that aims to raise the FDA's fiscal 2013 budget to $2.5 billion has gained support from the Alliance for a Stronger FDA, which calls it "strongly favorable" to the agency. The measure, which includes the new user fees for medical devices, drugs and biologics, provides $10 million to allow the agency to beef up its inspections in China, the group said. In-PharmaTechnologist.com (3/18) LinkedInFacebookTwitterEmail this Story
  Society and Ethics 
  • Neuroscientist hopes virtual brain will unify research
    Neuroscientist Henry Markram is the brains behind Blue Brain, a web of nearly 10,000 virtual neurons designed to simulate living brain waves. Markram's next step, the Human Brain Project, will simulate an entire brain on a supercomputer. Critics say the project is poorly defined and premature, and will siphon scarce funds from other programs, but Markram sees his project as a unifying principle for other neuroscientists. The New York Times (tiered subscription model) (3/18) LinkedInFacebookTwitterEmail this Story
  On the FastTrack 
 

FasterCures / The Center for Accelerating Medical Solutions is a nonprofit think tank and catalyst for action that works across sectors and diseases to improve the effectiveness and efficiency of the medical research enterprise. FasterCures, a center of the Milken Institute, is nonpartisan and independent of interest groups.

Subscriber Tools
     
Print friendly format | Web version | Search past news | Briefs by date | Privacy policy

Contact Us
FasterCures / The Center for Accelerating Medical Solutions
1101 New York Avenue, NW
Suite 620
Washington, DC 20005
(202) 336-8900 |  www.fastercures.org
 
Media Inquiries
Cecilia Arradaza
Director of Communications
202.336.8912
carradaza@fastercures.org
 

 
 
 Recent FasterCures SmartBrief issues:   Lead Editor:  Lisa Gough
     
Distributed by:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information